GSE140768 BMI1 inhibition 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE140768_BMI1 inhibition_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE140768_BMI1 inhibition_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE140768_BMI1 inhibition_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE140768_BMI1 inhibition_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

NBPF member 26

Gene

SCO-spondin, pseudogene

Gene

SATB2 antisense RNA 1

Gene

SDHA pseudogene 4

Gene

PDXDC2P-NPIPB14P readthrough, transcribed pseudogene

Gene

phosphatidylinositol 4-kinase alpha pseudogene 2

Gene

phosphatidylinositol 4-kinase alpha pseudogene 1

Gene

SDHA pseudogene 3

Gene

polycystin 1, transient receptor potential channel interacting pseudogene 2

Gene

BMS1 pseudogene 14


  • Gene

    SCO-spondin, pseudogene


  • Gene

    SATB2 antisense RNA 1


  • Gene

    SDHA pseudogene 4


  • Gene

    PDXDC2P-NPIPB14P readthrough, transcribed pseudogene


  • Gene

    phosphatidylinositol 4-kinase alpha pseudogene 2


  • Gene

    phosphatidylinositol 4-kinase alpha pseudogene 1


  • Gene

    SDHA pseudogene 3


  • Gene

    polycystin 1, transient receptor potential channel interacting pseudogene 2


  • Gene

    BMS1 pseudogene 14

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.